Dedicated MR vendor Fonar is in compliance with the Nasdaq stock exchange, ending concerns that the company would be delisted.
Fonar enters Nasdaq good graces
Dedicated MR vendor Fonar is in compliance with the Nasdaq stock exchange, ending concerns that the company would be delisted. At issue was whether Fonar satisfied Nasdaq Listing Rule 5550(b)(3), which requires companies on the exchange to have a minimum $500,000 of net income from continuing operations in the latest fiscal year. Fonar’s most recent Form 10-K, filed Oct. 5, showed net income from continuing operations of $1.1 million for the fiscal year ended June 30, 2009.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.